4.62 - SHINE - Ibrutinib BR vs BR; Limitations to the trial

Plenary Session

English - June 04, 2022 19:33 - 18 minutes - 16.5 MB - ★★★★★ - 722 ratings
Science Health & Fitness Medicine medicine oncology health policy Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: 4.61 - How CDC's Vaccine Safety Missed Cases Of Myocarditis

Next Episode: 4.63 - ASCO22 - DYNAMIC - Can CT DNA Allow us to Give Less Chemo in Stage II Colon Cancer

Continuous vs. Fixed, 3 vs 2, PFS is the primary endpoint
No OS
Bad crossover
Lots to discuss here
I will be covering all the major ASCO papers on @PlenarySession
Subscribe to my substack https://vinayprasadmdmph.substack.com/